ARCA biopharma, Inc. (ABIO)
Largest Insider Buys in Sector
ABIO Stock Price History Chart
ABIO Stock Performance
About ARCA biopharma, Inc.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Insider Activity of ARCA biopharma, Inc.
Over the last 12 months, insiders at ARCA biopharma, Inc. have bought $0 and sold $0 worth of ARCA biopharma, Inc. stock.
On average, over the past 5 years, insiders at ARCA biopharma, Inc. have bought $677,553 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 18,110 shares for transaction amount of $41,383 was made by Ma-Weaver Jacob () on 2022‑05‑23.
List of Insider Buy and Sell Transactions, ARCA biopharma, Inc.
| 2022-05-23 | Ma-Weaver Jacob | 18,110 0.1238% | $2.29 | $41,383 | -5.60% | |||
| 2022-05-18 | Ma-Weaver Jacob | 1 <0.0001% | $2.25 | $2 | -3.93% | |||
| 2022-05-12 | Ma-Weaver Jacob | 14,000 0.0971% | $2.29 | $32,119 | -4.35% | |||
| 2022-05-10 | Ma-Weaver Jacob | 20,979 0.144% | $2.28 | $47,927 | -3.90% | |||
| 2022-05-05 | Ma-Weaver Jacob | 57,998 0.403% | $2.28 | $132,392 | -2.19% | |||
| 2022-04-28 | Ma-Weaver Jacob | 8,974 0.062% | $2.30 | $20,644 | -1.73% | |||
| 2022-04-25 | Ma-Weaver Jacob | 13,751 0.0896% | $2.29 | $31,508 | -6.97% | |||
| 2022-04-18 | Ma-Weaver Jacob | 9,119 0.0631% | $2.31 | $21,080 | -1.29% | |||
| 2022-04-14 | Ma-Weaver Jacob | 17,410 0.1202% | $2.33 | $40,546 | -2.14% | |||
| 2022-04-08 | Ma-Weaver Jacob | 30,660 0.2066% | $2.31 | $70,852 | -3.78% | |||
| 2022-04-05 | Ma-Weaver Jacob | 26,806 0.1851% | $2.30 | $61,603 | -0.87% | |||
| 2022-04-04 | Funicular Fund, LP | 122,342 0.8194% | $2.26 | $276,309 | -1.71% | |||
| 2022-04-01 | Funicular Fund, LP | 122,342 0.8716% | $2.26 | $276,309 | +4.55% | |||
| 2021-11-22 | Ozeroff Christopher David | S.V.P., General Counsel | 50,000 0.3523% | $2.26 | $113,210 | +3.14% | ||
| 2021-05-12 | CONWAY ROBERT E | director | 10,000 0.0695% | $3.19 | $31,947 | -18.50% | ||
| 2021-05-05 | CONWAY ROBERT E | director | 10,000 0.0691% | $3.23 | $32,345 | -19.08% | ||
| 2020-12-18 | CONWAY ROBERT E | director | 10,000 0.221% | $4.16 | $41,630 | -16.75% | ||
| 2020-09-25 | CONWAY ROBERT E | director | 5,000 0.0789% | $4.28 | $21,400 | -16.26% | ||
| 2020-09-22 | CONWAY ROBERT E | director | 3,056 0.051% | $4.66 | $14,241 | -17.97% | ||
| 2020-09-21 | CONWAY ROBERT E | director | 10,000 0.1703% | $4.77 | $47,660 | -17.82% |
Insider Historical Profitability
| Ma-Weaver Jacob | 2515601 17.3477% | $3.47 | 11 | 0 | <0.0001% | |
| mccormack riley | 10 percent owner | 2100000 14.4817% | $3.47 | 1 | 6 | <0.0001% |
| Funicular Fund, LP | 1944993 13.4127% | $3.47 | 2 | 0 | +1.42% | |
| FORMELA JEAN FRANCOIS | director | 1337612 9.2242% | $3.47 | 0 | 2 | |
| Atlas Venture Fund VII L P | 10 percent owner | 1337612 9.2242% | $3.47 | 0 | 1 | |
| Grais Linda S | director | 491889 3.3921% | $3.47 | 0 | 1 | |
| Skyline Venture Partners Qualified Purchaser Fund IV L P | 335400 2.3129% | $3.47 | 0 | 6 | ||
| Lowe David George | director | 129600 0.8937% | $3.47 | 0 | 9 | |
| Wheeler Patrick M | Chief Financial Officer | 101510 0.7% | $3.47 | 0 | 1 | |
| LOVE TED W | C.E.O | 57289 0.3951% | $3.47 | 1 | 0 | |
| Ozeroff Christopher David | S.V.P., General Counsel | 50970 0.3515% | $3.47 | 1 | 6 | +3.14% |
| ZUBROW BARRY L | director | 50000 0.3448% | $3.47 | 1 | 0 | |
| CONWAY ROBERT E | director | 50000 0.3448% | $3.47 | 8 | 0 | <0.0001% |
| BRISTOW MICHAEL R | Pres. & Chief Executive Offic | 41155 0.2838% | $3.47 | 1 | 8 | |
| Keuer Thomas A | Chief Operating Officer | 13153 0.0907% | $3.47 | 0 | 10 | |
| MITCHELL DANIEL J | director | 11000 0.0759% | $3.47 | 1 | 0 | |
| LEVY MICHAEL D | Sr. VP Research & Development | 9000 0.0621% | $3.47 | 1 | 0 | |
| Titus Gary | V.P. and Chief Acctg Officer | 2633 0.0182% | $3.47 | 1 | 4 | |
| Sakoda Jon | director | 0 0% | $3.47 | 0 | 1 | |
| MOTT DAVID M | 10 percent owner | 0 0% | $3.47 | 0 | 1 | |
| BARRIS PETER J | 10 percent owner | 0 0% | $3.47 | 0 | 1 | |
| BASKETT FOREST | 10 percent owner | 0 0% | $3.47 | 0 | 1 | |
| MAKOWER JOSHUA | director | 0 0% | $3.47 | 0 | 1 | |
| SOBEL BURTON E | director | 0 0% | $3.47 | 0 | 4 | |
| Selby Brian L. | VP, Finance | 0 0% | $3.47 | 0 | 9 | |
| SANDELL SCOTT D | 10 percent owner | 0 0% | $3.47 | 0 | 1 | |
| Sonsini Peter W. | 10 percent owner | 0 0% | $3.47 | 0 | 1 | |
| Viswanathan Ravi | 10 percent owner | 0 0% | $3.47 | 0 | 1 | |
| FALBERG KATHRYN E | CFO and COO | 0 0% | $3.47 | 0 | 1 | |
| Florence Anthony A. Jr. | 10 percent owner | 0 0% | $3.47 | 0 | 1 | |
| Growth Equity Opportunities IV, LLC | 10 percent owner | 0 0% | $3.47 | 0 | 1 | |
| VENROCK HEALTHCARE CAPITAL PARTNERS LP | 10 percent owner | 0 0% | $3.47 | 0 | 2 |
Institutional Investor Ownership
| Western Standard Llc | $2.48M | 9.72 | 1.41M | 0% | +$0 | 3.35 | |
| Bml Capital Management Llc | $1.24M | 4.87 | 706,930 | 0% | +$0 | 0.95 | |
| The Vanguard Group | $798,332.00 | 3.13 | 453,598 | 0% | +$0 | <0.0001 | |
| BlackRock | $406,979.00 | 1.59 | 231,238 | -0.29% | -$1,184.48 | <0.0001 | |
| Geode Capital Management | $253,418.00 | 0.98 | 142,349 | 0% | +$0 | <0.0001 | |
| Renaissance Technologies | $116,000.00 | 0.45 | 65,699 | +14.66% | +$14,831.28 | <0.0001 | |
| State Street | $106,278.00 | 0.41 | 59,707 | -16.07% | -$20,345.31 | <0.0001 | |
| Dimensional Fund Advisors | $75,654.00 | 0.29 | 42,502 | -0.03% | -$21.36 | <0.0001 | |
| Standard Life | $57,131.00 | 0.22 | 32,461 | 0% | +$0 | <0.0001 | |
| Northern Trust | $36,928.00 | 0.15 | 20,982 | 0% | +$0 | <0.0001 | |
| Charles Schwab | $26,679.00 | 0.1 | 14,988 | 0% | +$0 | <0.0001 | |
| Hrt Financial Llc | $22,000.00 | 0.09 | 12,714 | New | +$22,000.00 | <0.0001 | |
| Tower Research Capital | $5,412.00 | 0.02 | 3,075 | +1.72% | +$91.52 | <0.0001 | |
| Citadel Advisors LLC | $2,179.00 | 0.01 | 1,224 | -80.63% | -$9,072.05 | <0.0001 | |
| Parallel Advisors, LLC | $429.00 | <0.01 | 244 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $141.00 | <0.01 | 80 | +1.27% | +$1.76 | <0.0001 | |
| Bank of America | $310.00 | <0.01 | 176 | +309.3% | +$234.26 | <0.0001 | |
| Fidelity Investments | $358.00 | <0.01 | 201 | New | +$358.00 | <0.0001 | |
| Qube Research & Technologies | $89.00 | <0.01 | 50 | 0% | +$0 | <0.0001 | |
| Simplex Trading Llc | $0 | <0.01 | 3 | -97% | -$0 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 56 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $32.00 | <0.01 | 18 | +12.5% | +$3.56 | <0.0001 |